Eton Pharmaceuticals shares are trading higher after the company expanded its Rare Disease Portfolio through the acquisition of U.S. Commercialization Rights to HEMANGEOL Oral Solution. Also, HC Wainwright &amp; Co. maintained its Buy rating on the stock and raised the price target from $35 to $37.

ARKG

<p>Eton Pharmaceuticals shares are trading higher after the company expanded its Rare Disease Portfolio through the acquisition of U.S. Commercialization Rights to HEMANGEOL Oral Solution. Also, HC Wainwright & Co. maintained its Buy rating on the stock and raised the price target from $35 to $37.</p>

benzinga_article

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

Eton Pharmaceuticals

VanEck Biotech ETF

SPDR S&P Biotech

VG Health

iShares Biotechnology ETF

iShares Global Healthcare

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Health Care Select Sector SPDR

News